Menlo Therapeutics Inc
4085 Campbell Avenue
About Menlo Therapeutics IncMenlo Therapeutics Inc. (formerly Tigercat Pharma, Inc.) is a clinical stage pharmaceutical company focused on the development and commercialization of serlopitant for the treatment of severe, chronic pruritus (itch). Serlopitant (VPD-737) is a potent oral NK1 receptor antagonist that Menlo Therapeutics exclusively licensed from Merck in 2012. Menlo Therapeutics investors include Vivo Capital, F-Prime Capital, Presidio Partners and Remeditex Ventures.
CEO: Steven Basta
CMO: Paul Kwon
Currently, there are no jobs for this employer on BioSpace.
Browse jobs with BioSpace Featured Employers here.